Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma

Página do item simplificado
dc.contributor.authorPetrilli, Antonio Sergio [UNIFESP]
dc.contributor.authorCypriano, Monica [UNIFESP]
dc.contributor.authorDantas, Lenice Silva [UNIFESP]
dc.contributor.authorLee, Lúcia Martino [UNIFESP]
dc.contributor.authorLuisi, Maria Flávio Augusto Vercillo [UNIFESP]
dc.contributor.authorSilva, Katia Veronica Torres B. [UNIFESP]
dc.contributor.authorPereira, Carlos Alberto Pires [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2015-06-14T13:29:59Z
dc.date.available2015-06-14T13:29:59Z
dc.date.issued2003-04-01
dc.description.abstractBACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections.en
dc.description.affiliationFederal University of São Paulo Division of Infectious Disease Pediatric Oncology Institute
dc.description.affiliationUnifespUNIFESP, Division of Infectious Disease Pediatric Oncology Institute
dc.description.sourceSciELO
dc.format.extent111-120
dc.identifierhttp://dx.doi.org/10.1590/S1413-86702003000200003
dc.identifier.citationBrazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 7, n. 2, p. 111-120, 2003.
dc.identifier.doi10.1590/S1413-86702003000200003
dc.identifier.fileS1413-86702003000200003.pdf
dc.identifier.issn1413-8670
dc.identifier.scieloS1413-86702003000200003
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/1697
dc.language.isoeng
dc.publisherBrazilian Society of Infectious Diseases
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFeveren
dc.subjectneutropeniaen
dc.subjectleukemiaen
dc.subjectlymphomaen
dc.subjectticarcillinen
dc.subjectceftriaxoneen
dc.titleEvaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphomaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1413-86702003000200003.pdf
Tamanho:
35.77 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPE - Artigos